Editorial

ARTICLE

Auteur(s) : Jean Durlach 

Editor-in-Chief, Magnesium Research 
President, SDRM

It includes original experimental, clinical and review papers in biology, carcinology, chronopathology, hematology, internal medicine, nephrology, neurology, nutrition, physiology, rhumatology and therapeutics. 

They originate from many part of the world. 

1. Three original experimental papers are presented. 

S.I. Katsumata et al. (Tokyo, Japan) investigated the effect of dietary magnesium supplementation on bone loss in rats fed a high phosphorous diet. It seems that dietary magnesium supplementation suppressed bone resorption due to high phosphorous diet. 

H. Matsusaki et al. (Tokyo, Japan) examined the effects of high calcium intake on bone metabolism in magnesium deficient rats. It seems that high calcium intake had no preventive effect on alteration of bone metabolism in magnesium deficient rats. 

C. Feillet-Coudray et al. (Clermont-Ferrand, Wroclaw, Roma ; France, Poland, Italy) demonstrated that the increased magnesium content observed in erythrocytes of tumor-bearing mice is not due to decreased magnesium efflux or increased magnesium influx. On the contrary erythrocytres from tumor-bearing mice displayed higher magnesium efflux. It is possible that the increased magnesium content is due, at least partly, to enhanced erythropoiesis induced by tumor associated anemia. 

2. Next come one original clinical paper. 

J. Durlach et al. (Paris, France) stressed the importance of the new concept of headache due to photosensitive magnesium depletion whose main clinical form is headache with photophobia (Migraine and Tension Type Headache particularly). The treatment must associate the classical treatment of headache with a balanced magnesium status and the control of hypofunction of the biological clock through various darkness therapies : physiologic, psychotherapic, physiotherapic or pharmacologic stimulation of the biological clock, or partial darkness mimicking agents, such as melatonin.

3. Next come one review paper. 

L. Massey (Spokane, WA, USA) entically evaluated the experimental evidence and clinical trial outcomes as the basis for the use of magnesium supplements as therapy for calcium oxalate urolithiasis. Clinical trial evidence does not justify the use of magnesium supplementation as a sole therapy for calcium oxalate kidney stones in a general patient population. Clinical trials should focus on patients that are likely to be magnesium deficient. However the addition of magnesium to potassium citrate therapy improves outcomes. 

4. Abstracts of the last issue of the Journal of Japanese Society for Magnesium Research and of the IX^th International Convention of Polish Magnesium Society, a Book Review, the Calendar of Magnesium Meetings followed by the Forthcoming Contents complete this second 2005 issue of our quarterly international journal Magnesium Research.